Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.
作者： M. Salih Deveci , Güzin Deveci
DOI: 10.1007/S10120-007-0418-7
关键词: Pathology 、 Surgical oncology 、 Antigen 、 Gene 、 Epithelial cell adhesion molecule 、 Monoclonal antibody 、 Carcinoma 、 Medicine 、 Gastrectomy 、 Cancer research 、 Clinical trial
摘要: Background MK-1, the target molecule of FU-MK-1, is encoded by GA733-2 gene, which currently being used as a in clinical trials for gastric, intestinal and biliary cancer treatment with monoclonal antibodies. Also interest p53, protein that has been intensively investigated relation to particular types tumors, patterns metastases, tumor stage, prognosis.
springer.com
paperity.org参考文章(26)
Izumi Kumagai, Hironori Abe, Fumiko Arakawa, Toshio Kudo, Masahide Kuroki, Aruto Ueno, Hisanobu Matsumoto, Motomu Kuroki, Kohei Tsumoto, Ryutaro Asano, T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Research. ,vol. 22, pp. 769- 776 ,(2002)
Garces A, Fenoglio Cm, Mesa-Tejada R, Bennett Sj, Pascal Rr, Carcinoembryonic antigen: immunohistologic identification in invasive and intraepithelial carcinomas of the lung. Archives of Pathology & Laboratory Medicine. ,vol. 101, pp. 568- ,(1977)
Setsuo Hirohashi, Masaaki Terada, Takashi Sugimura, Toshimasa Kihana, Gen Tamura, Kazuhiro Nomura, Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Research. ,vol. 51, pp. 3056- 3058 ,(1991)
BV Joypaul, D Hopwood, EL Newman, S Qureshi, A Grant, SA Ogston, DP Lane, A Cuschieri, THE PROGNOSTIC SIGNIFICANCE OF THE ACCUMULATION OF P53 TUMOUR-SUPPRESSOR GENE PROTEIN IN GASTRIC ADENOCARCINOMA British Journal of Cancer. ,vol. 69, pp. 943- 946 ,(1994) , 10.1038/BJC.1994.182
Y Kakeji, D Korenaga, S Tsujitani, H Baba, H Anai, Y Maehara, K Sugimachi, Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. British Journal of Cancer. ,vol. 67, pp. 589- 593 ,(1993) , 10.1038/BJC.1993.108
F Chang, S Syrjänen, A Tervahauta, K Syrjänen, Tumourigenesis associated with the p53 tumour suppressor gene. British Journal of Cancer. ,vol. 68, pp. 653- 661 ,(1993) , 10.1038/BJC.1993.404
Hironobu Sasano, Fumiko Date, Akio Imatani, Shigeru Asaki, Hiroshi Nagura, Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells Human Pathology. ,vol. 24, pp. 584- 589 ,(1993) , 10.1016/0046-8177(93)90236-A
Vijay Yajnik, Pathology and genetics of tumors of the digestive system Gastroenterology. ,vol. 121, pp. 1258- ,(2001) , 10.1016/S0016-5085(01)70019-4
Ryoji Watanabe, Hiroshi Johzaki, Hiroshi Iwasaki, Masahiro Kikuchi, Seiyo Ikeda, A new tumor-associated antigen defined by a monoclonal antibody directed to gastric adenocarcinoma. Cancer. ,vol. 71, pp. 2439- 2447 ,(1993) , 10.1002/1097-0142(19930415)71:8<2439::AID-CNCR2820710803>3.0.CO;2-W
B.G. Schneider, V. Pekkel, C.H. Shelton, D.R. Pulitzer, D.C. Allred, S.G. Hilsenbeck, C.H. Hensel, H.A. Rodr�guez-Mart�nez, M.E. Guti�rrez-D�az C., p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Archiv. ,vol. 424, pp. 187- 193 ,(1994) , 10.1007/BF00193499